China's Fosun to Buy out Henlius Biotech, Values it at US$ 1.71 billion

ACQUISITION - REUTERS- Chinese conglomerate Fosun International will buy the remaining stake in Shanghai Henlius Biotech that it does not already own in a deal that values the Hong Kong-listed drugmaker at HK$13.37 billion ($1.71 billion), the companies said on Monday.

Fosun International, through its unit Shanghai Fosun Pharmaceutical, is offering HK$24.60 per Henlius share, which reflects a premium of 30.6% to the target's last close.

Read Also: China's Xiaomi to Start Deliveries of Its First EV Model, Shares Soar